DOCOMO-DIGITAL
17.2.2016 10:56:13 CET | Business Wire | Press release
In January 2016, Japan’s largest mobile network operator, NTT DOCOMO, INC., has set up DOCOMO Digital Ltd. in London as a new global business operation.
DOCOMO Digital will exhibit at Mobile World Congress in Barcelona next week. It is the European based operation unit of NTT DOCOMO and an advanced mobile commerce ecosystem-enabling platformer which aims to encourage financial inclusion for citizens worldwide by bringing together mobile network operators, digital and real-world merchants, financial services providers, regulators and other parties to make consumer transactions convenient, safe and with universal coverage.
DOCOMO Digital has created the tools and infrastructure to provide seamless mobile commerce solutions for ecosystem participants across the world. The company actively addresses regulatory and commercial issues between parties and operates a global banking-grade technical platform on which mobile commerce ecosystems can be securely built and managed.
Hiroyuki Sato, CEO of DOCOMO Digital, says: “Since 2009 we have patiently built and developed DOCOMO Digital into an organisation that can drive the evolution of mobile commerce. We are excited about the future of mobile and believe that it is the most logical pathway to achieving true, global financial inclusion for everyone.”
Utilising the expertise from parent company NTT DOCOMO as well as from the acquisition of international mobile commerce providers and specialists, including net mobile AG and Buongiorno SpA, DOCOMO Digital has created a comprehensive suite of products and services.
The company supports stakeholders by building and operating digital media platforms, mobile payment services, such as direct carrier billing and mobile wallet, as well as offering technical support, mobile commerce consultancy and financial services through banking and e-money licenses.
DOCOMO Digital believes it is important to make its platforms safe for all users and fair to operators and merchants. It has worked with regulators, banks and merchants to ensure the goods and services that people want and need are accessible to them.
Hiroyuki Sato continues: “We have brought together key assets and capabilities to enable m-commerce for mobile network operators, digital and real-world service providers, merchants and regulators. In a nutshell, we provide expertise, technology and operational services to bring to life next generation m-commerce platforms.”
A number of global commerce partnerships have already begun, including projects with major carriers, retailers, content providers and social network platforms.
The company’s goal to achieve truly global financial inclusion extends to banked and unbanked customers. It believes that being able to contribute to and participate in the digital economy should be universal, regardless of whether individuals have a bank account or not.
DOCOMO Digital is Japanese-owned and benefits from its experience in Japan, but it is an international global company and present on 6 continents through nearly 1,000 people of 50 nationalities in 35 offices.
DOCOMO Digital will be exhibiting at Mobile World Congress in Barcelona from 22nd to 25th February 2016, and can be seen at Hall 8.1 Stand 8.1B51.
-ENDS-
Issued on behalf of DOCOMO Digital by Jargon PR. For more information, multimedia or to arrange an interview, please contact:
About DOCOMO Digital
DOCOMO Digital is the operation unit for the global digital ecosystem platform business operations of NTT DOCOMO, Japan’s largest mobile operator. Leveraging 15 years of experience in mobile payment and mobile content business in Japan, as well as in the global market, DOCOMO Digital focuses on m-commerce enabler platform development which offers to digital and non-digital merchants safe, reliable and convenient payment and financing options for their consumers, and robust marketing solutions to attract and convert their target customers. For more information please visit www.docomodigital.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160217005631/en/
Contact:
DOCOMO Digital
Dennis Heisig
Press Officer
Dennis.Heisig@docomodigital.com
Phone:
+49 162 406 32 42
or
Tom Johnson
Jargon PR
tom.johnson@jargonpr.com
Phone:
+44 7960 209361
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom